

Amendments to the Claims:

Applicants propose to amend Claim 1 herein. Please note that all claims currently pending and under consideration in the referenced application are shown below. Please enter these claims as amended. This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A method for treating a human immunodeficiency virus infection comprising administering an effective amount of a composition comprising:
a member selected from the group consisting of:
 - (i) a compound represented by the formula $(T_m-A-X-B)-H_n$ or $(A-X-B-T_m)-H_n$, wherein A is a protein synthesis inactivating toxin that is inactive until X is digested; X is a peptide susceptible to digestion by a human immunodeficiency virus protease; B is a lectin or a segment thereof, T is a targeting moiety, H is a hydrophobic agent, m is 0 or an integer of at least 1, and n is 0 or an integer of at least 1,
 - (ii) a compound having a lectin or hydrophobic agent and further represented by the formula $N-X-A$ or $A-X-N$, wherein A is a protein synthesis inactivating protein that is inactive until X is digested, X is a peptide susceptible to digestion by a human immunodeficiency virus protease, and N is an adenine moiety or functional equivalent thereof, and
 - (iii) mixtures of (i) and (ii); and
a pharmaceutically acceptable carrier.
2. (Original) The method of claim 1 wherein A is a ricin A chain and B is a ricin B chain.
3. (Original) The method of claim 1 wherein X is a member selected from the group consisting of SEQ ID NO:12 and SEQ ID NO: 13.

4. (Original) The method of claim 1 wherein said targeting moiety is a member selected from the group consisting of antigen-binding proteins, viral surface components and segments thereof, proteins that bind viral surface components, growth factors, lectins, and carbohydrates.

5. (Original) The method of claim 4 wherein said targeting moiety is an antigen-binding protein that binds the CD4 glycoprotein.

6. (Original) The method of claim 5 wherein the protein that binds the CD4 glycoprotein is gp120 or a segment thereof.

7. (Original) The method of claim 1 wherein said targeting moiety is a GAG protein segment.

8. (Original) The method of claim 1 wherein said hydrophobic agent is a member selected from the group consisting of bile acids, sterols, and saturated and unsaturated fatty acids.

9. (Original) The method of claim 8 wherein said hydrophobic agent is a bile acid selected from the group consisting of cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, isoursodeoxycholic acid, lagodeoxycholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid, hyodeoxycholic acid, and mixtures thereof.

10. (Original) The method of claim 8 wherein said hydrophobic agent is a sterol selected from the group consisting of cholestanol, coprostanol, cholesterol, epicholesterol, ergosterol, ergocalciferol, and mixtures thereof.

11. (Original) The method of claim 8 wherein said hydrophobic agent is a saturated or unsaturated fatty acid comprising about 4 to 20 carbon atoms.

12. (Original) The method of claim 11 wherein said saturated or unsaturated fatty acid is a member selected from the group consisting of butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, eleostearic acid, and mixtures thereof.